Thrivent Financial For Lutherans Cytokinetics Inc Transaction History

Thrivent Financial For Lutherans

$45.7 Billion
Q2 2025

A detailed history of Thrivent Financial For Lutherans transactions in Cytokinetics Inc stock. As of the latest transaction made, Thrivent Financial For Lutherans holds 28,119 shares of CYTK stock, worth $1.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

28,119

Previous 27,670 1.62%

Holding current value

$1.68 Million

Previous $1.11 Million 16.46%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 26, 2025	BUY	$29.84 - $42.92 $13,398 - $19,271	449 Added 1.62%	28,119 $929,000
Q1 2025 Aug 26, 2025	BUY	$40.19 - $51.12 $1.11 Million - $1.41 Million	27,670 New	27,670 $1.11 Million
Q4 2024 Feb 10, 2025	BUY	$46.36 - $58.62 $5,841 - $7,386	126 Added 0.46%	27,768 $1.31 Million
Q3 2024 Nov 07, 2024	SELL	$51.22 - $60.16 $3,175 - $3,729	-62 Reduced 0.22%	27,642 $1.46 Million
Q2 2024 Aug 13, 2024	BUY	$47.86 - $75.05 $149,897 - $235,056	3,132 Added 12.75%	27,704 $1.5 Million
Q1 2024 May 14, 2024	SELL	$63.75 - $108.06 $4 Million - $6.79 Million	-62,802 Reduced 71.88%	24,572 $1.72 Million
Q4 2023 Feb 14, 2024	SELL	$26.88 - $83.49 $11,961 - $37,153	-445 Reduced 0.51%	87,374 $7.3 Million
Q3 2023 Nov 14, 2023	SELL	$29.46 - $36.61 $108,236 - $134,505	-3,674 Reduced 4.02%	87,819 $2.59 Million
Q2 2023 Aug 14, 2023	SELL	$32.62 - $40.75 $74,634 - $93,236	-2,288 Reduced 2.44%	91,493 $2.98 Million
Q1 2023 May 17, 2023	SELL	$33.36 - $45.71 $109,654 - $150,248	-3,287 Reduced 3.39%	93,781 $3.3 Million
Q4 2022 Feb 08, 2023	SELL	$35.77 - $51.11 $8,942 - $12,777	-250 Reduced 0.26%	97,068 $4.45 Million
Q3 2022 Nov 14, 2022	BUY	$38.54 - $54.52 $507,494 - $717,919	13,168 Added 15.65%	97,318 $4.72 Million
Q2 2022 Aug 16, 2022	BUY	$33.93 - $48.92 $538,231 - $776,017	15,863 Added 23.23%	84,150 $3.31 Million
Q1 2022 May 13, 2022	BUY	$29.74 - $46.0 $654 - $1,012	22 Added 0.03%	68,287 $2.51 Million
Q4 2021 Feb 16, 2022	BUY	$34.35 - $46.38 $26,140 - $35,295	761 Added 1.13%	68,265 $3.11 Million
Q3 2021 Nov 15, 2021	BUY	$18.54 - $35.74 $164,227 - $316,584	8,858 Added 15.1%	67,504 $2.41 Million
Q2 2021 Aug 19, 2021	BUY	$19.79 - $26.99 $4,571 - $6,234	231 Added 0.4%	58,646 $1.16 Million
Q1 2021 May 17, 2021	SELL	$18.57 - $25.68 $3,175 - $4,391	-171 Reduced 0.29%	58,415 $1.36 Million
Q4 2020 Feb 16, 2021	BUY	$15.26 - $28.61 $1,892 - $3,547	124 Added 0.21%	58,586 $1.22 Million
Q3 2020 Nov 10, 2020	BUY	$20.58 - $28.96 $178,737 - $251,517	8,685 Added 17.45%	58,462 $1.27 Million
Q2 2020 Aug 12, 2020	BUY	$11.15 - $24.64 $2,910 - $6,431	261 Added 0.53%	49,777 $1.17 Million
Q1 2020 May 15, 2020	BUY	$8.75 - $16.3 $21,630 - $40,293	2,472 Added 5.25%	49,516 $584,000
Q4 2019 Feb 13, 2020	BUY	$7.95 - $11.84 $5,445 - $8,110	685 Added 1.48%	47,044 $499,000
Q3 2019 Nov 14, 2019	BUY	$10.82 - $14.25 $11,642 - $15,333	1,076 Added 2.38%	46,359 $528,000
Q2 2019 Aug 13, 2019	BUY	$7.95 - $11.25 $27,666 - $39,150	3,480 Added 8.32%	45,283 $509,000
Q1 2019 May 14, 2019	BUY	$5.95 - $10.19 $18,748 - $32,108	3,151 Added 8.15%	41,803 $338,000
Q4 2018 Feb 15, 2019	BUY	$5.91 - $9.29 $18,480 - $29,049	3,127 Added 8.8%	38,652 $244,000
Q3 2018 Nov 15, 2018	BUY	$6.4 - $9.85 $3,686 - $5,673	576 Added 1.65%	35,525 $350,000
Q2 2018 Aug 14, 2018	BUY	$6.9 - $9.9 $14,096 - $20,225	2,043 Added 6.21%	34,949 $290,000
Q1 2018 May 08, 2018	BUY	$7.2 - $10.05 $11,880 - $16,582	1,650 Added 5.28%	32,906 $237,000
Q4 2017 Feb 14, 2018	BUY	$7.25 - $15.65 $4,466 - $9,640	616 Added 2.01%	31,256 $255,000
Q3 2017 Nov 14, 2017	BUY	$12.0 - $15.0 $367,680 - $459,600	30,640	30,640 $444,000

Others Institutions Holding CYTK

# of Institutions

371

Shares Held

129M

Call Options Held

3.62M

Put Options Held

1.14M

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $5.61B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.

Account

Thrivent Financial For Lutherans Cytokinetics Inc Transaction History